Selective intake. This tort is in a developing or borderline posture. MTAA runs campaigns here on a case-by-case basis — talk to us about whether paid acquisition currently fits your docket.
Prenatal acetaminophen litigation centers on allegations that in-utero exposure to acetaminophen — the active ingredient in Tylenol and hundreds of generic products sold by manufacturers including Johnson & Johnson — is associated with an elevated risk of Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) in children. For plaintiff firms that have evaluated the science and are actively building dockets, the question is no longer whether the litigation exists — it is whether paid acquisition can deliver qualified claimants at a volume and cost that makes docket growth viable.
MTAA classifies prenatal acetaminophen as a borderline intake opportunity, meaning the campaign architecture and qualification funnel matter enormously. Firms that run undifferentiated broad-reach ads will accumulate high volumes of weak leads; firms that run tightly scoped creative with a disciplined intake screen will build a docket worth litigating. That distinction is exactly where a purpose-built Meta acquisition program adds value.
The prenatal acetaminophen litigation targets a wide universe of potential claimants because acetaminophen is among the most commonly used over-the-counter analgesics during pregnancy, and both ASD and ADHD are diagnoses that affect a substantial share of the pediatric population. Johnson & Johnson, as the brand-name manufacturer of Tylenol, is the anchor defendant, with generic manufacturers also named in many complaints. The core allegation is that manufacturers failed to adequately warn pregnant consumers of the potential neurodevelopmental risks associated with prenatal use.
Because the litigation involves a ubiquitous consumer product and two distinct — and separately weighted — injury categories, the case mix within any docket can vary significantly. ASD diagnoses generally represent the stronger end of the injury spectrum in this litigation; ADHD-only cases, or cases where prenatal use is difficult to document, sit at the borderline. Firms building this docket need an intake process that can efficiently sort between those tiers, and a claimant-acquisition strategy that skews toward the stronger profile from the first touchpoint.
Who a campaign targets
Primary target — strongest campaign focus: Mothers who used acetaminophen during pregnancy and whose child has received a formal diagnosis of Autism Spectrum Disorder, particularly where use was significant and can be documented (medical records, pharmacy records, or consistent self-report).
Secondary target — viable with strong documentation: Mothers with documented, significant prenatal acetaminophen use whose child carries an ADHD diagnosis supported by clinical records.
Borderline — requires careful intake screening: Claimants presenting with ADHD as the sole diagnosis, or where prenatal use was minimal or difficult to corroborate. These leads require a more rigorous intake conversation before a firm commits resources.
Campaign framing for the firm: Audience qualification should be built around three pillars — confirmed prenatal use, a documented ASD or ADHD diagnosis in the child, and the ability to substantiate the exposure period. Creative and landing-page copy should prompt self-selection on all three before a lead is passed to intake staff.
How MTAA runs Acetaminophen / Tylenol (Prenatal) campaigns
The creative challenge in prenatal acetaminophen advertising is specificity: the product is so common that nearly every mother who took any pain reliever during pregnancy will feel the ad speaks to her, regardless of whether her child has a qualifying diagnosis. MTAA addresses this by building creative that leads with the child's diagnosis — ASD or ADHD — rather than leaning on product recognition alone. Ads that open with the neurodevelopmental outcome and then connect it to prenatal acetaminophen use naturally filter for the claimant profile that matters, reducing junk volume before a single intake call is made. On Meta, this approach allows us to layer behavioral and interest-based signals around parenting communities, special-needs advocacy groups, and health-conscious parent demographics to reach mothers who are already engaged with their child's diagnosis journey.
Intake fit is a central consideration for this tort. Because the borderline tier — ADHD-only, minimal documented use — can represent a meaningful share of raw response, the handoff between ad click and intake staff needs a qualification layer: a short pre-screen that captures diagnosis type, approximate timing and frequency of acetaminophen use during pregnancy, and whether any medical documentation exists. MTAA builds this screen into the landing-page flow so that intake teams receive leads pre-sorted by case strength, not a flat list. For firms running this tort alongside a broader docket, that efficiency at the top of the funnel is what keeps cost-per-signed case manageable.
Pricing
Mass Tort Ad Agency runs Acetaminophen / Tylenol (Prenatal) campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
Acetaminophen / Tylenol (Prenatal) advertising — common questions
Why is prenatal acetaminophen classified as 'borderline' intake — should we be running ads at all?
Borderline does not mean the litigation lacks merit or that advertising is inadvisable — it means the claimant pool is heterogeneous and campaign design has to do more work than it would for a tort with a single, clearly defined injury. Firms that have evaluated the science and are committed to building a docket can absolutely run paid acquisition profitably here. The key is that creative, landing-page copy, and the intake pre-screen all work together to surface the stronger ASD-plus-documented-use profile and flag the weaker ADHD-only or low-documentation leads before they consume attorney time.
How does MTAA differentiate between ASD claimants and ADHD-only claimants in the ad funnel?
We build the qualification logic into the response path, not just the intake call. Ad creative is written to speak to parents of children with neurodevelopmental diagnoses broadly, but the landing page asks respondents to identify their child's specific diagnosis before they submit contact information. That single data point lets intake teams prioritize ASD leads and apply additional scrutiny to ADHD-only submissions. We can also run separate ad sets with diagnosis-specific messaging to further pre-sort volume by case tier.
Documentation of prenatal use is a challenge — how does the campaign account for that?
Documented use is a case-strength factor, not a binary gate at the top of the funnel. The pre-screen we build into the landing-page flow asks about the frequency and timing of acetaminophen use during pregnancy and whether the respondent has any records — pharmacy, OB, or otherwise — that reflect it. Leads who report significant, consistent use are flagged as higher priority; those who report minimal or uncertain use are passed to intake with that context already noted. This gives your intake team the information they need to have a productive first conversation rather than discovering the documentation gap mid-call.
Johnson & Johnson is the named brand manufacturer — does that affect how we can advertise?
Meta advertising for plaintiff litigation does not require naming defendants in ad copy, and in most cases it is strategically better not to. Our creative focuses on the injury — the child's ASD or ADHD diagnosis — and the prenatal exposure mechanism, which is the factual core of the claim. This approach reaches claimants who used any brand of acetaminophen during pregnancy, including generics, which broadens the addressable audience without creating compliance friction around brand-name references in paid social copy.
Ready to run Acetaminophen / Tylenol (Prenatal) campaigns?
We build, run, and qualify Acetaminophen / Tylenol (Prenatal) claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.